Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089013 | 0.93 | PRMT5 (0.38) | NOD2NOD1PRMT5WDR77AAK1 | |
| SCHEMBL13144338 | 0.92 | NOD2 (0.39) | NOD2NOD1PRMT5WDR77AAK1 | |
| SCHEMBL13348212 | 0.89 | USP30 (0.40) | PRMT5WDR77AAK1USP30HIF1A | |
| SCHEMBL1565096 | 0.86 | USP30 (0.39) | PRMT5WDR77AAK1USP30HIF1A | |
| SCHEMBL3076889 | 0.85 | PRMT5 (0.38) | NOD2NOD1PRMT5WDR77AAK1 | |
| SCHEMBL22724916 | 0.84 | USP30 (0.40) | PRMT5WDR77AAK1USP30HIF1A | |
| SCHEMBL7920031 | 0.82 | UCHL1 (0.36) | NOD2NOD1PRMT5WDR77USP30 | |
| SCHEMBL17206150 | 0.82 | MAPT (0.45) | NOD2NOD1UCHL1HIF1AMEN1 | |
| SCHEMBL12042732 | 0.81 | NOD2 (0.52) | NOD2NOD1NR1H2MEN1KMT2A | |
| SCHEMBL3451480 | 0.81 | USP30 (0.40) | PRMT5WDR77AAK1USP30HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2009007751-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | NOD2 111/4885NOD1 324/4885PRMT5 3689/4885 |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MTOR, PIK3CA, PIK3CD | NOD2 2232/4885NOD1 2594/4885PRMT5 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.